UY32303A - Tiolactamas y sus usos - Google Patents
Tiolactamas y sus usosInfo
- Publication number
- UY32303A UY32303A UY0001032303A UY32303A UY32303A UY 32303 A UY32303 A UY 32303A UY 0001032303 A UY0001032303 A UY 0001032303A UY 32303 A UY32303 A UY 32303A UY 32303 A UY32303 A UY 32303A
- Authority
- UY
- Uruguay
- Prior art keywords
- tiolactamas
- compounds
- plk
- inflammatory
- inhibitors
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20094508P | 2008-12-05 | 2008-12-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY32303A true UY32303A (es) | 2010-05-31 |
Family
ID=42076993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001032303A UY32303A (es) | 2008-12-05 | 2009-12-07 | Tiolactamas y sus usos |
Country Status (7)
| Country | Link |
|---|---|
| US (6) | US7998952B2 (enExample) |
| EP (1) | EP2373657B1 (enExample) |
| JP (2) | JP5684719B2 (enExample) |
| AR (1) | AR074487A1 (enExample) |
| TW (1) | TW201026703A (enExample) |
| UY (1) | UY32303A (enExample) |
| WO (1) | WO2010065134A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1799684B1 (en) * | 2004-10-04 | 2014-12-03 | Millennium Pharmaceuticals, Inc. | Lactam compounds useful as protein kinase inhibitors |
| GB201604970D0 (en) | 2016-03-23 | 2016-05-04 | Syngenta Participations Ag | Improvements in or relating to organic compounds |
| CN111763170B (zh) * | 2020-07-10 | 2022-03-18 | 江苏豪森药业集团有限公司 | 氟马替尼中间体的制备方法 |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06172355A (ja) * | 1992-04-14 | 1994-06-21 | Mect Corp | ピリミジン誘導体およびそれを有効成分とする血小板凝集阻止剤 |
| DE4332168A1 (de) | 1993-02-22 | 1995-03-23 | Thomae Gmbh Dr K | Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| US5686445A (en) | 1993-07-29 | 1997-11-11 | American Cyanamid Company | Pyridobenzoxazepine and pyridobenzothiazepine vasopressin antagonists |
| US5428040A (en) | 1993-08-31 | 1995-06-27 | The Du Pont Merck Pharmaceutical Company | Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents |
| US5925635A (en) * | 1996-04-17 | 1999-07-20 | Dupont Pharmaceuticals Company | N-(amidinophenyl) cyclourea analogs as factor XA inhibitors |
| WO1997047601A1 (en) | 1996-06-11 | 1997-12-18 | Yoshitomi Pharmaceutical Industries, Ltd. | Fused heterocyclic compounds and medicinal uses thereof |
| AU3296497A (en) * | 1996-06-13 | 1998-01-07 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| US6057329A (en) * | 1996-12-23 | 2000-05-02 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives |
| GB9713087D0 (en) * | 1997-06-20 | 1997-08-27 | Celltech Therapeutics Ltd | Chemical compounds |
| FR2804959B1 (fr) | 2000-02-15 | 2006-04-28 | Centre Nat Rech Scient | Utilisation de derives de paullones pour la fabrication de medicaments |
| US6369222B1 (en) | 2000-07-18 | 2002-04-09 | Hoffmann-La Roche Inc. | mGluR antagonists and a method for their synthesis |
| US6610677B2 (en) | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| WO2002088079A2 (en) | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
| US7105667B2 (en) | 2001-05-01 | 2006-09-12 | Bristol-Myers Squibb Co. | Fused heterocyclic compounds and use thereof |
| US6686352B2 (en) | 2001-05-18 | 2004-02-03 | Hoffmann-La Roche Inc. | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives |
| EP1552842A1 (en) | 2002-06-07 | 2005-07-13 | Kyowa Hakko Kogyo Co., Ltd. | Bicyclic pyrimidine derivatives |
| WO2004076424A1 (en) | 2003-02-27 | 2004-09-10 | Abbott Laboratories | Heterocyclic kinase inhibitors |
| JP2006528169A (ja) | 2003-07-21 | 2006-12-14 | ファイザー・プロダクツ・インク | ニコチン嗜癖を低減するヘテロアリール縮合アザ多環式化合物 |
| CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| PL1771450T3 (pl) * | 2004-05-14 | 2008-05-30 | Millennium Pharm Inc | Związki i sposoby do inhibicji postępu mitozy przez hamowanie kinazy Aurora |
| EP1799684B1 (en) | 2004-10-04 | 2014-12-03 | Millennium Pharmaceuticals, Inc. | Lactam compounds useful as protein kinase inhibitors |
| PE20070171A1 (es) | 2005-06-30 | 2007-03-08 | Boehringer Ingelheim Int | GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR Xa |
| CL2007003244A1 (es) * | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
-
2009
- 2009-12-04 TW TW098141596A patent/TW201026703A/zh unknown
- 2009-12-04 WO PCT/US2009/006391 patent/WO2010065134A1/en not_active Ceased
- 2009-12-04 EP EP09795577.7A patent/EP2373657B1/en active Active
- 2009-12-04 AR ARP090104716A patent/AR074487A1/es unknown
- 2009-12-04 JP JP2011539512A patent/JP5684719B2/ja not_active Expired - Fee Related
- 2009-12-04 US US12/631,144 patent/US7998952B2/en active Active
- 2009-12-07 UY UY0001032303A patent/UY32303A/es not_active Application Discontinuation
-
2011
- 2011-06-30 US US13/173,161 patent/US8268992B2/en active Active
-
2012
- 2012-08-09 US US13/570,486 patent/US8507667B2/en not_active Expired - Fee Related
- 2012-08-09 US US13/570,518 patent/US20120302551A1/en not_active Abandoned
-
2013
- 2013-11-07 US US14/074,506 patent/US20140194410A1/en not_active Abandoned
-
2014
- 2014-07-29 JP JP2014153744A patent/JP2014221824A/ja not_active Withdrawn
- 2014-10-29 US US14/526,699 patent/US20150175542A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US7998952B2 (en) | 2011-08-16 |
| AR074487A1 (es) | 2011-01-19 |
| US8268992B2 (en) | 2012-09-18 |
| US20100179126A1 (en) | 2010-07-15 |
| JP2012510990A (ja) | 2012-05-17 |
| US20120309743A1 (en) | 2012-12-06 |
| US8507667B2 (en) | 2013-08-13 |
| US20140194410A1 (en) | 2014-07-10 |
| EP2373657B1 (en) | 2016-09-14 |
| JP2014221824A (ja) | 2014-11-27 |
| US20110257157A1 (en) | 2011-10-20 |
| TW201026703A (en) | 2010-07-16 |
| JP5684719B2 (ja) | 2015-03-18 |
| US20150175542A1 (en) | 2015-06-25 |
| WO2010065134A1 (en) | 2010-06-10 |
| US20120302551A1 (en) | 2012-11-29 |
| EP2373657A1 (en) | 2011-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY32303A (es) | Tiolactamas y sus usos | |
| CO6690755A2 (es) | Heteroarilos como inhibidores de p13k | |
| CR20110028A (es) | Derivados de pirimidina como inhibidores de cinasa | |
| EP2603216A4 (en) | HETEROARYLE AND USES THEREOF | |
| EA201170252A1 (ru) | Амидофеноксиндазолы в качестве ингибиторов c-мет | |
| CR20110032A (es) | Derivados de tiofeno y tiazol y su uso como inhibidores de p13k | |
| DOP2011000217A (es) | Nuevas bencenosulfonamidas como bloqueadores de canales de calcio | |
| SI2321235T1 (sl) | Uporaba sestavka za pospeševanje strjevanja, ki vsebuje mehčalec | |
| SV2011003809A (es) | Derivados de heteroarilo como inhibidores de dgat1 | |
| MX2019008122A (es) | Derivados de aminas heterociclicas que inhiben la transduccion de se?al mediada por cinasa asociada con el receptor de interleucina-1. | |
| CR20120158A (es) | Compuestos de diòxido de iminotiadiazina como inhibidores de bace, composiciones y su uso. | |
| DOP2013000036A (es) | Derivados de ciclobutano como inhibidores de jak | |
| CO6321282A2 (es) | Derivados de piperidinilindol como inhibidores de aldosterona sintasa | |
| EA201171367A1 (ru) | Винилиндазолильные соединения | |
| DK3517534T3 (da) | Forbindelser, der er anvendelige til behandling af cancer | |
| DOP2011000076A (es) | Derivados de heteroaril amidas y su uso como activadores de glucoquinasa | |
| ECSP11010770A (es) | Compuesto heterocíclico y su uso | |
| GT200600035A (es) | Aminopiridinas como inhibidores de beta-secretasa | |
| DOP2013000082A (es) | Heteroarilos y sus usos | |
| CR11488A (es) | 4-fenilpiran 3,5-dionas, 4-feniltiopiran-3,5-dionas y 2-fenilciclohexan-1,3,5-trionas como herbicidas | |
| BRPI0815715A2 (pt) | compostos 5-(-4-(haloalcóxi)fenil)pirimidina-2-amina e composições como inibidores de quinases. | |
| CL2011000846A1 (es) | Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c. | |
| CR11416A (es) | Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos | |
| SV2009003373A (es) | COMPUESTOS AMINO-5-[-4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5- FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA REF. AM102759 | |
| EA201000219A1 (ru) | Способ и композиция для лечения в-клеточных пролиферативных нарушений |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20181219 |